Loading
Cytokines such as interleukin-2 or TNF fused to an antibody that homes to the tumour, aiming to concentrate the immune boost where it is needed and spare the rest of the body.
Systemic interleukin-2 and interferon were among the first cancer immunotherapies but were limited by severe toxicity. Immunocytokines fuse a cytokine to a tumour-targeting antibody or fragment so that it accumulates in tumour tissue; examples include L19-IL2 and L19-TNF (Philogen), which reached phase 3 in melanoma and soft tissue sarcoma, and engineered IL-2 and IL-12 variants with reduced systemic activity. Results have been mixed and no product is approved.
A cytokine domain is fused to an antibody against a tumour-associated antigen or stromal marker, delivering local immune activation after systemic dosing.
Daromun is a pair of antibody-linked immune messengers injected straight into melanoma deposits before surgery. In a phase 3 trial it lowered the chance of the melanoma coming back after the operation compared with surgery alone.
Query for this technology: (TITLE:"Immunocytokines" OR ABSTRACT:"Immunocytokines" OR TITLE:"antibody-cytokine fusions" OR ABSTRACT:"antibody-cytokine fusions") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Immunocytokines (antibody-cytokine fusions), not a curated reading list.
Shares Cytokines & engineered cytokines, Sarcomas (soft tissue, bone, GIST), Melanoma.
Shares Cytokines & engineered cytokines, Melanoma.
Shares Cytokines & engineered cytokines, Sarcomas (soft tissue, bone, GIST), Melanoma.
Shares Cytokines & engineered cytokines, Melanoma.
Shares Cytokines & engineered cytokines, Sarcomas (soft tissue, bone, GIST).
Shares Cytokines & engineered cytokines, Melanoma.
Shares Daromun, Sarcomas (soft tissue, bone, GIST), Melanoma.